生物科技公司Castle Biosciences, Inc.（纳斯达克股票代码：CSTL）今日盘中大跌14.21%，股价走势引发市场广泛关注。此次大跌主要源于公司公布的2025年第一季度财报未能达到市场预期，引发投资者对公司短期增长前景的担忧。
根据Castle Biosciences最新发布的财报显示，公司2025年第一季度调整后每股亏损为0.20美元，远低于分析师平均预期的0.07美元亏损。尽管公司第一季度营收同比增长20.6%，达到8799万美元，超过了分析师预期的8034万美元，但仍未能抵消盈利方面的失望表现。更令投资者担忧的是，公司本季度净亏损高达2585万美元，进一步加剧了市场的悲观情绪。
尽管Castle Biosciences今年以来股价已累计下跌超过27%，但分析师对该公司的长期前景仍保持乐观态度。目前，分析师对该公司股票的平均评级为"强力买入"，12个月目标价中位数为40.00美元。然而，考虑到本次财报业绩不佳，投资者可能需要重新评估公司的短期增长潜力。随着市场继续消化Castle Biosciences第一季度业绩，该股在未来几个交易日内可能会面临进一步的波动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.